Somatuline Depot FDA Approval History
FDA Approved: Yes (First approved August 30, 2007)
Brand name: Somatuline Depot
Generic name: lanreotide acetate
Dosage form: Injection
Company: Ipsen Biopharmaceuticals, Inc.
Treatment for: Acromegaly; Gastroenteropancreatic Neuroendocrine Tumors; Carcinoid Syndrome
Somatuline Depot (lanreotide) is a long acting somatostatin analogue indicated for the treatment of acromegaly, gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome.
Development timeline for Somatuline Depot
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.